Fosamax Osteonecrosis of the Jaw Settlement: California Fosamax Osteonecrosis of the Jaw Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Risks

For decades, general health and science information has served as the foundation for public understanding of medical treatments and their potential long-term effects. Within this broad domain, the focus has often been on the benefits of pharmaceutical interventions, such as bisphosphonates like Fosamax, which are widely prescribed to manage bone density loss. This legacy context emphasizes patient education and informed consent, highlighting the importance of recognizing when a treatment’s risks may outweigh its intended benefits. As awareness of adverse outcomes has grown, attention has shifted from general population health to specific, high-stakes scenarios. One such scenario involves the rare but serious condition of osteonecrosis of the jaw, which has been linked to prolonged bisphosphonate exposure.

Bridging to Occupational and Legal Concerns

This pivot naturally leads to a more targeted concern: the occupational exposure risk for individuals who may have been prescribed Fosamax over extended periods. In a mass production environment, where repetitive tasks and physical demands are common, the implications of such exposure become particularly relevant. Workers with a history of Fosamax use may face heightened vulnerability to jaw-related complications, especially when combined with dental procedures or minor trauma. This transition from general health awareness to occupational exposure concern underscores the need for careful monitoring and legal consideration in workplace settings.

Medical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, which can lead to reduced bone turnover. The jawbone has unique structural and cellular characteristics that may make it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the jawbone's distinct biology contributes to the development of ONJ in patients taking Fosamax.

Adequacy of Warnings and Settlement Considerations in California

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the incidence of ONJ is rare, and fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). The incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). For affected patients in California considering settlement-related options, several factors are relevant. The timeline between exposure to Fosamax and documented harm can vary widely, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who have developed ONJ after taking Fosamax may need to consider the adequacy of warnings provided by the manufacturer and whether those warnings were sufficient to inform patients and healthcare providers of the risk. The prescribing information does include warnings about ONJ, but the clinical presentation and diagnosis of ONJ can be challenging, and patients may not have been fully aware of the risk before starting treatment. Settlement considerations for affected patients may include the severity of the injury, the duration of treatment, and the presence of other risk factors. Patients should consult with a qualified attorney to understand their legal options and the potential for compensation. The evidence suggests that while ONJ is a rare complication of Fosamax therapy, it can have significant consequences for affected individuals, particularly those who undergo invasive dental procedures while on the medication.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. Osteonecrosis of the jaw (ONJ) is a rare but serious adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ involves bone death in the jaw and can occur spontaneously or after dental procedures. The risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the risk factors for developing ONJ from Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How soon after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms after starting Fosamax can vary from one day to several months. Most patients experience relief after stopping the drug, but some may have recurrence if rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What settlement options are available for California patients with Fosamax-related ONJ?

Patients in California who developed ONJ after taking Fosamax may consider legal options for compensation. Settlement considerations include severity of injury, duration of treatment, and presence of other risk factors. It is important to consult with a qualified attorney to understand eligibility and potential compensation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.